Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ANDA Pre-Submission Meetings Being Considered By FDA

Executive Summary

Designed to boost application quality, creating such meetings would be another sign of the evolution of the Office of Generic Drugs.

You may also be interested in...



CDER’s Sequestration Strategy Aided By 400 Missing FTEs

FDA’s ability to avoid furloughs under sequester is not good news, OND Director John Jenkins says, but instead is a sign of severe understaffing that already existed.

Generic User Fees Need Small Business Waiver, Firms Say; Congress May Agree

Small business owners say the GDUFA facility and other fees are too expensive, especially while waiting for ANDAs to be approved, but any small business waiver is unlikely until GDUFA II.

OxyContin’s Abuse-Deterrent Claims Strong, But Stronger Claims Possible

FDA reviewed all the categories of pre-marketing and post-marketing data outlined by guidance for abuse-deterrent opioids, but only in vitro and liking studies made it into the updated label.

Related Content

Topics

UsernamePublicRestriction

Register

PS055415

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel